Global Primary Sclerosing Cholangitis Market 2020 By Type [Classic PSC, Small-duct PSC, PSC associated with autoimmune hepatitis and others],By Treatment Type [Ursodeoxycholic acid, Obeticholic Acid, Methotrexate, Corticosteroids and Others], By Symptom Control[Antihistamines, Cholestyramine, Antibacterials, Opioid Antagonists, Colestipol and Others], By End- User[Hospital Pharmacies, Retail Pharmacies and Online Pharmacies]: Global Forecast to 2026 and COVID-19 Impact Outlook
Global Primary Sclerosing Cholangitis Market is valued at USD 121.8 Million in 2019 and expected to reach USD 156.9 Million by 2026 with the CAGR of 3.68 % over the forecast period.
Scope of the report
This report analyses the global market for Primary Sclerosing Cholangitis. The report will enable the user to understand and gain insights into the current and forecast market situation. The market is comprehensively analyzed by geography to give complete information on the global scenario. The qualitative and quantitative data provided in this study can help user understand which market segments, regions are expected to grow at higher rates, factors affecting the market and key opportunity areas. The report also includes competitive landscape of key players in the industry along with emerging trends in the market.
Key Players
Acorda Therapeutics, Inc., Gilead Sciences, Inc., NGM Biopharmaceuticals, Intercept Pharmaceuticals, Inc., Dr. Falk Pharma GmbH, ALLERGAN, Takeda Pharmaceutical Company Limited., DURECT CORPORATION, Conatus Pharmaceuticals, Inc., Sirnaomics, Inc., HighTide Therapeutics Inc., Glenmark, Impax Laboratories, LLC, Mylan N.V., Teva Pharmaceuticals Industries Ltd. and others
Above mentioned companies were scrutinized to assess competitive landscape of global Primary Sclerosing Cholangitis market. Report provides company profiles of each player. Each profile include company product portfolio,business overview, company governance, company financials, business strategies, manufacturing locations and production facilities, company sale, recent developments and strategic collaborations & partnerships, new product launch, company segments, application diversification and company strength and weakness analysis.
Review period: (2016-2026)
Historic Period: 2016 to 2019
Forecast Period: 2020 to 2026
Base Year: 2019
Unit: USD Million
This Primary Sclerosing Cholangitis market report provides insights on new trade regulations, import export analysis, industry value chain analysis, market size, consumption, production analysis, capacity analysis, regional and segment market share, product launches, product pipeline analysis, impact of Covid-19 on supply chain, key regions, untapped markets, patent analysis, product approvals, continuous innovations and developments in the market.
Regions
• North America: U.S., Canada and Rest of North America
• Europe: UK, France, Germany, Italy, Spain and Rest of Europe
• Asia Pacific: China, Japan, India, Australia, Southeast Asia and Rest of Asia Pacific
• Latin America: Brazil, Mexico, Argentina and Rest of Latin America
• Middle East and Africa: Gulf Countries, Israel, Africa and Rest of Middle East and Africa
Market Segmentation
• Type
o Classic PSC
o Small-duct PSC
o PSC associated with autoimmune hepatitis
• Treatment Type
o Ursodeoxycholic acid
o Obeticholic Acid
o Methotrexate
o Corticosteroids
o Others
• Symptom Control
o Antihistamines
o Cholestyramine
o Antibacterials
o Opioid Antagonists
o Colestipol
o Others
• End- User
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
Report Coverage
• An overview of the global Primary Sclerosing Cholangitis market
• In depth analysis of market dynamics and major factors such as drivers, restraints, opportunities and trends influencing the global market
• Global Primary Sclerosing Cholangitis market revenue data historic and forecast analysis (2016 to 2026)
• Characterization and quantification of the market segments for Primary Sclerosing Cholangitis market
• Market share analysis of key market participants and their competitive landscape
Important Questions Answered by Global Primary Sclerosing Cholangitis Market Report
• What is the impact of COVID 19 epidemic on the global Primary Sclerosing Cholangitis market?
• Which is mostly affected region, country?
• Which is the current largest and fastest-growing region?
• What is the market size and growth rate of the global Primary Sclerosing Cholangitis market?
• What are current factors affecting the growth of market?
• What are Key trends and opportunity areas?
• Within Primary Sclerosing Cholangitis market, which segments are fastest growing & emerging strongly? What are the drivers and restraints for each segment? What are vendor competencies by segment?
• What are the major strategies adopted by leading market companies?
• What are company challenges and essential success factors by marketsegment?
• How company offerings and supply chain capabilitiesare shifting to meetemerging market needs?
Table of Contents
1. Introduction
1.1. Report Description
1.2. Market Segmentation
1.3. Research Methodology
1.4. List of Abbreviations
2. Executive Summary
3. Market Overview
3.1. Market Definition
3.2. Market Scope
3.3. Market Drivers
3.4. Market Restraints
3.5. Market Opportunities and Trends
3.6. Porter’s five force analysis
3.7. SWOT Analysis
3.8. PEST Analysis
3.9. Patent Analysis
3.10. Impact of COVID 19 on Global Primary Sclerosing Cholangitis Market
4. Primary Sclerosing Cholangitis Market, By Type, Market Size and Forecast 2016 -2026 (USD Million)
4.1. Global Primary Sclerosing Cholangitis Market By Type, 2016 -2026 (USD Million)
4.1.1. Global Primary Sclerosing Cholangitis Market By Classic PSC
4.1.2. Global Primary Sclerosing Cholangitis Market By Small-duct PSC
4.1.3. Global Primary Sclerosing Cholangitis Market By PSC associated with autoimmune hepatitis
4.2. Global Primary Sclerosing Cholangitis Market By Type Share, 2016 -2026 (%)
5. Primary Sclerosing Cholangitis Market, By Symptom Control, Market Size and Forecast 2016 -2026 (USD Million)
5.1. Global Primary Sclerosing Cholangitis Market By Symptom Control, 2016 -2026 (USD Million)
5.1.1. Global Primary Sclerosing Cholangitis Market By Antihistamines
5.1.2. Global Primary Sclerosing Cholangitis Market By Cholestyramine
5.1.3. Global Primary Sclerosing Cholangitis Market By Antibacterials
5.1.4. Global Primary Sclerosing Cholangitis Market By Opioid Antagonists
5.1.5. Global Primary Sclerosing Cholangitis Market By Colestipol
5.1.6. Global Primary Sclerosing Cholangitis Market By Others
5.2. Global Primary Sclerosing Cholangitis Market By Symptom Control Share, 2016 -2026 (%)
6. Primary Sclerosing Cholangitis Market, By Treatment Type, Market Size and Forecast 2016 -2026 (USD Million)
6.1. Global Primary Sclerosing Cholangitis Market By Treatment Type, 2016 -2026 (USD Million)
6.1.1. Global Primary Sclerosing Cholangitis Market By Ursodeoxycholic acid
6.1.2. Global Primary Sclerosing Cholangitis Market By Obeticholic Acid
6.1.3. Global Primary Sclerosing Cholangitis Market By Methotrexate
6.1.4. Global Primary Sclerosing Cholangitis Market By Corticosteroids
6.1.5. Global Primary Sclerosing Cholangitis Market By Others
6.2. Global Primary Sclerosing Cholangitis Market By Treatment Type Share, 2016 -2026 (%)
7. Primary Sclerosing Cholangitis Market, By End- User, Market Size and Forecast 2016 -2026 (USD Million)
7.1. Global Primary Sclerosing Cholangitis Market By End- User, 2016 -2026 (USD Million)
7.1.1. Global Primary Sclerosing Cholangitis Market By Hospital Pharmacies
7.1.2. Global Primary Sclerosing Cholangitis Market By Retail Pharmacies
7.1.3. Global Primary Sclerosing Cholangitis Market By Online Pharmacies
7.2. Global Primary Sclerosing Cholangitis Market By End- User Share, 2016 -2026 (%)
8. Primary Sclerosing Cholangitis Market, By Region Market Size and Forecast 2016 -2026
8.1. NORTH AMERICA
8.1.1. Key Findings
8.1.2. Impact of COVID 19
8.1.3. Key market trends, growth factors and opportunities
8.1.4. North America Primary Sclerosing Cholangitis Market by Country 2016 -2026 (USD Million)
8.1.5. North America Primary Sclerosing Cholangitis Market By Type 2016 -2026 (USD Million)
8.1.6. North America Primary Sclerosing Cholangitis Market By Treatment Type 2016 -2026 (USD Million)
8.1.7. North America Primary Sclerosing Cholangitis Market By Symptom Control 2016 -2026 (USD Million)
8.1.8. North America Primary Sclerosing Cholangitis Market By End- User 2016 -2026 (USD Million)
8.2. EUROPE
8.2.1. Key Findings
8.2.2. Impact of COVID 19
8.2.3. Key market trends, growth factors and opportunities
8.2.4. Europe Primary Sclerosing Cholangitis Market by Country 2016 -2026 (USD Million)
8.2.5. Europe Primary Sclerosing Cholangitis Market By Type 2016 -2026 (USD Million)
8.2.6. Europe Primary Sclerosing Cholangitis Market By Treatment Type 2016 -2026 (USD Million)
8.2.7. Europe Primary Sclerosing Cholangitis Market By Symptom Control 2016 -2026 (USD Million)
8.2.8. Europe Primary Sclerosing Cholangitis Market By End- User 2016 -2026 (USD Million)
8.3. ASIA PACIFIC
8.3.1. Key Findings
8.3.2. Impact of COVID 19
8.3.3. Key market trends, growth factors and opportunities
8.3.4. Asia Pacific Primary Sclerosing Cholangitis Market by Country 2016 -2026 (USD Million)
8.3.5. Asia Pacific Primary Sclerosing Cholangitis Market By Type 2016 -2026 (USD Million)
8.3.6. Asia Pacific Primary Sclerosing Cholangitis Market By Treatment Type 2016 -2026 (USD Million)
8.3.7. Asia Pacific Primary Sclerosing Cholangitis Market By Symptom Control 2016 -2026 (USD Million)
8.3.8. Asia Pacific Primary Sclerosing Cholangitis Market By End- User 2016 -2026 (USD Million)
8.4. LATIN AMERICA
8.4.1. Key Findings
8.4.2. Impact of COVID 19
8.4.3. Key market trends, growth factors and opportunities
8.4.4. Latin America Primary Sclerosing Cholangitis Market by Country 2016 -2026 (USD Million)
8.4.5. Latin America Primary Sclerosing Cholangitis Market By Type 2016 -2026 (USD Million)
8.4.6. Latin America Primary Sclerosing Cholangitis Market By Treatment Type 2016 -2026 (USD Million)
8.4.7. Latin America Primary Sclerosing Cholangitis Market By Symptom Control 2016 -2026 (USD Million)
8.4.8. Latin America Primary Sclerosing Cholangitis Market By End- User 2016 -2026 (USD Million)
8.5. MIDDLE EAST AND AFRICA
8.5.1. Key Findings
8.5.2. Impact of COVID 19
8.5.3. Key market trends, growth factors and opportunities
8.5.4. Middle East and Africa Primary Sclerosing Cholangitis Market by Country 2016 -2026 (USD Million)
8.5.5. Middle East and Africa Primary Sclerosing Cholangitis Market By Type 2016 -2026 (USD Million)
8.5.6. Middle East and Africa Primary Sclerosing Cholangitis Market By Treatment Type 2016 -2026 (USD Million)
8.5.7. Middle East and Africa Primary Sclerosing Cholangitis Market By Symptom Control 2016 -2026 (USD Million)
8.5.8. Middle East and Africa Primary Sclerosing Cholangitis Market By End- User 2016 -2026 (USD Million)
9. Competitive Landscape Analysis
9.1. Global Primary Sclerosing Cholangitis Market Company Revenue, (USD Million), 2016-2019
9.2. Global Primary Sclerosing Cholangitis Market Company Share, (%), 2016-2019
10. Company Profiles
10.1. Acorda Therapeutics, Inc.
10.2. Gilead Sciences, Inc.
10.3. NGM Biopharmaceuticals
10.4. Intercept Pharmaceuticals, Inc.
10.5. Dr. Falk Pharma GmbH
10.6. ALLERGAN
10.7. Takeda Pharmaceutical Company Limited.
10.8. DURECT CORPORATION
10.9. Conatus Pharmaceuticals, Inc.
10.10. Sirnaomics, Inc.
10.11. HighTide Therapeutics Inc.
10.12. Glenmark
10.13. Impax Laboratories, LLC
10.14. Mylan N.V.
10.15. Teva Pharmaceuticals Industries Ltd.
10.16. Others
11. Appendix
12. List of Tables
13. List of Figures
